Rachel Humphrey's most recent trade in Pyxis Oncology Inc was a trade of 45,867 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 24, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Pyxis Oncology Inc | Rachel Humphrey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2026 | 45,867 | 45,867 | - | - | Stock Option (Right to Buy) | |
| Pyxis Oncology Inc | Rachel Humphrey | Director | Sale of securities on an exchange or to another person at price $ 1.03 per share. | 14 Apr 2025 | 13,896 | 81,309 | - | 1.0 | 14,362 | Common Stock |
| Pyxis Oncology Inc | Rachel Humphrey | Director | Sale of securities on an exchange or to another person at price $ 0.97 per share. | 14 Apr 2025 | 1,400 | 95,405 | - | 1.0 | 1,362 | Common Stock |
| Pyxis Oncology Inc | Rachel Humphrey | Director | Sale of securities on an exchange or to another person at price $ 0.97 per share. | 14 Apr 2025 | 200 | 95,205 | - | 1.0 | 194 | Common Stock |
| Pyxis Oncology Inc | Rachel Humphrey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 36,979 | 36,979 | - | - | Stock Option (Right to Buy) | |
| Pyxis Oncology Inc | Rachel Humphrey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2024 | 38,741 | 96,805 | - | 0 | Common Stock | |
| Pyxis Oncology Inc | Rachel Humphrey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 58,064 | 58,064 | - | 0 | Common Stock | |
| Pyxis Oncology Inc | Rachel Humphrey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2022 | 236,220 | 236,220 | - | - | Stock Option (Right to Buy) |